We used the Veterans Health Administration (VA) HIV Clinical Case Registry (CCR) to evaluate the association between annual CD4 averages and all-cause mortality in HIV-infected veterans during their initial episode of suppressive highly active antiretroviral therapy (HAART). We observed 1083 deaths in 14 769 patients. Unadjusted mortality rates in the top and bottom CD4 quintiles differed significantly from the mid CD4 strata. Mortality in the top CD4 quintile (720 cells/mm 3 ) was 14.1/1000 patient-years, 95% confidence interval (CI): 10.1-18.2, compared with 20.4 (CI: 15.5-25.3) in the next lower CD4 stratum (530-719 cells/mm 3 ). This difference was significant in Cox proportional hazards model, controlling for demographics, hepatitis co-infections, low-level viremia, HAART adherence, and refill rates of individual antiretrovirals (HR: 1.4, CI: 1.13-1.73). Our results support early HAART initiation as advocated by the current US treatment guidelines for HIV infection.
Introduction
Owing to the recent development of safer and more potent antiretroviral therapy (ART) regimens, long-term stable suppression of viremia below the level of detection has become the therapeutic default for HIV-infected patients. It is unclear whether permanent virologic suppression using highly active antiretroviral therapy (HAART) will suffice to fully restore life expectancy. According to a recent Dutch publication, only 0.4 to 1.5 years of life are lost attributable to HIV infection if HAART is initiated early. 1 Other large European retrospective analyses recently failed to show the differences in age-adjusted mortality rates between the general and HIV-infected population with CD4 counts >500 cells/mm 3 . [2] [3] [4] In contrast, other cohort analyses recently indicated that up to 10 to 15 years of life may be lost due chronic HIV infection even if viral replication is fully controlled and HAART was started in more recent years. [5] [6] [7] The CD4 values achieved during long-term HAART are better predictors of all-cause mortality than baseline CD4 counts, 8 even though they are strongly correlated. 9 It is not known whether there is a mortality impact of different CD4 counts within the normal range (500 cells/mm 3 ). Herein, we evaluated the contribution of peripheral CD4 counts on all-cause mortality in a large population of older, virologically suppressed predominantly male Americans with a high prevalence of comorbidities including hepatitis B (HBV) and C virus (HCV) coinfection. 10 Our patients may be well suited to serve as a model for the aging HIV-infected population in resource-rich settings.
Methods
We used the Clinical Case Registry (CCR) for HIV-infected US Veterans, which contains all nonnarrative clinical data for patients receiving care in the Veterans Health Administration network. 11 It includes laboratory values and vital signs as well as clinic utilization codes, pharmacy benefits management codes, codes for procedural terminology, and International Classification of Diseases, Ninth Revision (ICD-9) codes. Our observation period was fron January 1, 1995 to December 31, 2009 . Patients were included in the analysis if they met the following criteria: (1) prescription of first-time HAART 14 days within the VA system, (2) clinical follow-up time 18 months, (3) 1 available HIV viral load (VL) result <400 copies/mL within 18 months after HAART initiation, and (4) 1 CD4 measurement during virologic control. Highly active ART was defined as simultaneous prescription of either 2 nucleoside reverse transcriptase inhibitors (NRTIs) and 1 antiretroviral (ARV) drug of a different class, triple-class therapy, zidovudine (ZDV) containing triple-NRTI regimens, or dual-therapy with a boosted protease inhibitor and a nonnucleoside reverse transcriptase inhibitor.
Follow-up time started at first time initiation of HAART within the VA system. Death date and occurrence of clinical AIDS were recorded and updated locally at VA facilities. End of clinical follow-up was defined as death or the last record for CD4 count or VL measurement, sodium or hematocrit measurement, vital sign record, or clinic visit code. Patients were censored at the time of virologic failure defined as the first of 2 consecutive VL measurements 400 copies/mL or any measurement 1000 copies/mL.
Presence or absence of HBV infection was determined by evidence for positive surface antigen or HBV-DNA polymerase chain reaction (PCR) ever, HCV status was determined by a combination of ICD-9 codes, serologic, and PCR laboratory values (proof of chronicity was required for neither). Baseline VL and CD4 counts were defined as the closest value before or at the day of HAART initiation (if within 90 days). When absolute CD4 values were missing, they were calculated from CD4 percentages and absolute lymphocyte values of differential blood counts. For the statistical analysis, we used time updated annual CD4 averages derived by the area under the curve (AUC) method. This was updated every 6 months after HAART initiation (0-1 years, 0.5-1.5 years, 1-2 years, 1.5-2.5 years, etc), incorporating all available CD4 counts after HAART initiation. The CD4 area under the curve (AUC) averages were categorized into quintiles determined by the value reached 1 year before the end of follow-up.
As patients with isolated VL blips 400 to 1000 copies or consecutive VL values <400 copies/mL were only censored if they met the criteria for virologic failure, we calculated cumulative and annual percentages of detectable low level viremia <1000 copies/mL per year in a similar fashion as that of CD4 AUC averages.
Annual and cumulative use rates of all licensed individual ARV components were tabulated by refill history, accounting for early refills and ARV drugs dispensed during hospitalizations. Highly active ART adherence was defined as the percentage of days in which the patient had sufficient antiretroviral supplies in his or her possession to take a complete HAART regimen.
Statistical Analysis
Data cleaning and statistical analyses were conducted with SPSS version 18 and 20 (IBM SPSS Inc, Chicago, Illinois). We calculated the unadjusted annual mortality rates and tabulated them by 1 year time lagged CD4 quintile reached. We compared our rates with a calculated mortality rate of a race, gender, and agematched segment of the US population derived from 2007 CDC life tables. 12 To assess the association between CD4 quintile reached and death, we constructed a Cox model using lowlevel viremia, ARV use rates, and HAART adherence as continuous time-dependent covariates. As immunologic and virologic deterioration and altered ARV use could be a consequence of terminal disease, all time-dependent variables were entered by 1 year time lag. Missing values for time-dependent variables were handled by linear extrapolation wherever framed by existing values; otherwise the last value was carried forward.
As the CCR contains no narrative data, it is inherently difficult to exclude patients that received HAART outside of the VA system before entering the cohort. This subjects all CCR analyses to potential lead-in bias. We addressed this issue with 2 sensitivity analyses (1) by excluding patients with prior non-HAART ARV drug exposure within the VA system and (2) by the additional exclusion of patients whose VL was <10 000 copies/mL before HAART initiation.
Results
Of the 32 195 veterans who had ever received HAART inside the VA system, 14 769 achieved virologic suppression for 18 months and were eligible for analysis, contributing 68 606 patient-years. The median duration of virologic suppression was 3.3 years (interquartile range [IQR] 2-5.9 years) during which we observed 1083 deaths 18 months after HAART initiation. Demographic characteristics are displayed in Table 1 .
The overall unadjusted mortality rate after 18 months of HAART was 22. In univariate analysis, time updated CD4 averages carried higher hazard ratios (HRs) and narrower CIs for death than baseline CD4 values. Older age, baseline viremia, HBV, and HCV coinfection were associated with shorter survival, while higher cumulative and recent HAART adherence and the use of certain antiretroviral components were associated with longer survival.
In multivariate analysis, baseline CD4 counts were not predictive of death. Compared with the top CD4 quintile, patients in the next highest quintile (530-719 CD4 cells/mm 3 ) had an HR of 1.4 (CI: 1.13-1.73) for death. The CIs of the HRs within the 3 middle CD4 quintiles (250-719 CD4 cells/mm 3 ) overlapped, but patients in the lowest CD4 quintile (<250 CD4 cells/mm 3 ) had a significantly higher risk of death (HR: 2.46; CI: 1.99-3.01). Older age, higher cumulative HAART adherence, HBV and HCV coinfection, and calendar year of HAART initiation remained predictive of death in the multivariate model (Table 2) . Recent (but not cumulative) stavudine (d4T) use (HR: 1.32, CI: 1.12-1.55) was independently associated with death. In contrast, neither the baseline HIV RNA values nor the extent of low-level viremia while on treatment significantly altered the risk of death (Table 2 ).
In the 2 sensitivity analyses restricted to ARV-naive patients and additionally to patients with baseline VLs 10 000 copies mL, the baseline CD4 counts were again not statistically significant in multivariate analysis. The values and distribution of the HRs for the time-updated CD4 quintiles were similar to the overall study population (Supplemental Table 1 ).
We tabulated the recovery of CD4 AUC averages in the subgroup of ARV-naive patients with baseline viremia 10 000 copies/mL. Although few patients starting HAART with baseline CD4 counts <350 cells/mm 3 reached CD4 averages 720 cells/mm 3 and the majority of patients initiating HAART between 350 and 499 CD4 cells/mm 3 remained <720 CD4 cells/mm 3 for most of the study period, almost 75% of patients with baseline CD4 counts 500 reached CD4 AUC averages 720 cells/mm 3 beyond 5 years of HAART ( Figure 3 ).
Discussion
In contrast to earlier 9 and more recent 13 reports of a CD4 count plateau after 4 to 5 years on HAART, several cohort analyses 14, 15 including our own data show continuing CD4count increases for 8 to 10 years on uninterrupted HAART, regardless of the baseline CD4 count. Both time-updated CD4 values and time-averaged or cumulative CD4 exposure have previously been shown to be predictive of incident non-AIDS-defining cancers. 16 To address the volatility of single CD4 count measurements that fluctuate with postural state or rest 17 and intermittent episodes of inflammation, 18 we calculated the annual AUC averages that were updated semiannually.
In a study on German immune-discordant patients with CD4 counts <200 cells/mm 3 , new AIDS-defining events were rare beyond the first year of fully suppressive HAART. 19 Deaths after serious non-AIDS events have been found to outnumber AIDS-related deaths 2:1 in virologically suppressed patients on HAART. 20 Most of these deaths have been shown to be related to increased rates of either non-AIDS-defining cancers 16 or cardiovascular disease, 21 which may be partially driven by chronic immune activation 22 that may persist in lymphatic tissues for up to 10 years on continuous HAART. 23 We found that HRs for all-cause mortality at both ends of the CD4 spectrum (<250 and 720 CD4 cells/mm 3 ) markedly deviated from the mid CD4 range. While increased mortality for the low end of the CD4 spectrum is well established for stably suppressed HIV infection, the finding of a mortality gradient at an upper CD4 threshold >700 cells/mm 3 is not. Most large cohort analyses have not differentiated between different CD4 strata within the ''normalized'' CD4 range >500 cells/ mm 3 . 3, 4 However, what is considered ''normal'' for HIVnegative populations may not apply to chronic HIV infection. Possible explanations for the mortality difference in patients with normalized CD4 counts include the persistence of subclinical immunodeficiency at the lower end of the normal CD4 spectrum and a negative correlation between CD4þ counts and immune activation at the higher end. We decided against the inclusion of a comorbidity index as a covariate as the incidence of HIV-associated non-AIDS complications may lie in the causal pathway between CD4 recovery and risk of death. As have other investigators, we also found an increased risk of death in patients with HBV and HCV coinfection. 25 Our finding of an independent mortality risk for recent d4T use is novel and concerning, as this drug is still widely prescribed in resource-limited settings. In concordance with other studies, higher baseline HIV RNA values did not significantly alter the risk of death, 26 nor did the extent of low-level viremia on treatment. Higher HAART adherence was protective of death, possibly because it is a better surrogate marker of stable interruption of viral replication than infrequently measured plasma viremia. Although adherence was not directly measured, pharmacy refill data have been shown to be a reliable surrogate. 27 While the baseline CD4 counts were not our primary focus of interest and the number of ARV-naive patients in our study was not big enough to discern mortality differences between the different baseline CD4 strata, our results indirectly support treatment initiation at high CD4 counts, as patients with baseline CD4 counts 350 to 499 cells/mm 3 had a much reduced likelihood of reaching optimal CD4 averages 720 CD4 cells/mm 3 . This may explain their higher mortality risk that was reported in the NA-ACCORD study. 28 Our results thus indirectly support early HAART initiation as advocated by the current US treatment guidelines for HIV infection. 29, 30 The strengths of our study include uniform data collection on exposures and outcomes across the VA system, a novel approach to address the intraindividual variability in CD4 values, and the inclusion of measured HAART adherence and low-level viremia as continuous covariates. Our study has several limitations. Our data did not allow us to directly identify patients already taking HAART prescribed from the outside of the VA system. Extensive chart reviews have previously shown that their share comprises <25%. 10 We analyzed all patients after the first initiation of HAART within the VA system including those with potential HAART exposure from the outside and prior non-HAART ARV exposure within the VA system. While this subjects our analysis to lead-in bias, sensitivity analyses showed that the mortality risk conferred by suboptimal CD4 AUC averages was reduced neither by excluding patients with prior HAART ARV exposure within the VA system nor by the additional exclusion of patients who could have taken HAART from outside the VA system (VL < 10 000/mL at HAART initiation).
24
We only analyzed the first episode of virologic suppression after initial HAART. Although this approach did not allow for extended follow-up time and may result in an overrepresentation of events during the early years of HAART, it emulates current conditions as most contemporary ARV regimens have become very durable and virologic failure has become the exception.
Our data did not allow us to control for intravenous drug use (IVDU), which has been shown to be a strong predictor of death. 1 Even though the proportion of HCV coinfected patients in our cohort was very high, a recent analysis of HCV-infected US veterans revealed that only 15% engaged in ongoing drug abuse of any kind. 31 While absolute CD8 values or CD4/CD8 ratios may provide additional prognostic information for death in patients on HAART, 32 indirectly confirming an earlier report for CD4 percentage values, 33 we have recently shown that the inclusion of CD8 and CD4/CD8 subpopulations in the model did not substantially change the mortality risk conferred by suboptimal CD4 recovery. 34 Also, as our study population comprised 98% male, our results may not be generalizable to women.
In conclusion, ''low-normal'' CD4 counts >500 cells/mm 3 did not confer the same mortality benefit as ''high-normal'' CD4 counts, that is, at or above the median value for HIVuninfected populations. Yet, these high-normal CD4 counts were only reliably reached in patients who started HAART at a CD4 count >500 cells/mm 3 .
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